Rothenberg, Marc E.Klion, Amy D.Roufosse, Florence E.Kahn, Jean EmmanuelWeller, PeterSimon, Hans-UweSchwartz, Lawrence B.Rosenwasser, Lanny J.Ring, JohannesGriffin, Elaine F.Haig, Ann E.Frewer, Paul I.H.Parkin, Jacqueline M.Gleich, Gerald J.2016-09-302008Rothenberg, Marc E., Amy D. Klion, Florence E. Roufosse, Jean Emmanuel Kahn, Peter F. Weller, Hans-Uwe Simon, Lawrence B. Schwartz, et al. 2008. “Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab.” New England Journal of Medicine 358 (12) (March 20): 1215–1228. doi:10.1056/nejmoa070812.0028-4793http://nrs.harvard.edu/urn-3:HUL.InstRepos:28702415The hypereosinophilic syndrome is a group of diseases characterized by persistent blood eosinophilia, defined as more than 1500 cells per microliter with end-organ involvement and no recognized secondary cause. Although most patients have a response to corticosteroids, side effects are common and can lead to considerable morbidity.en-USJournal Article2016-09-3010.1056/NEJMoa070812